{
    "clinical_study": {
        "@rank": "105877", 
        "acronym": "ARMOR", 
        "arm_group": [
            {
                "arm_group_label": "Standard of Care (SOC) with Midostaurin", 
                "arm_group_type": "Experimental", 
                "description": "Patients will receive standard of care in the post SCT setting in addition to Midostaurin 50mg twice a day for 12 months (cycles)."
            }, 
            {
                "arm_group_label": "Standard of Care (SOC)", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients will receive standard of care alone in the post SCT setting"
            }
        ], 
        "brief_summary": {
            "textblock": "To determine if the addition of midostaurin (PKC412) to Standard of Care (SOC) therapy\n      reduces relapse in FLT3-ITD mutated AML patients receiving an allogenetic hematopoietic stem\n      cell transplant,"
        }, 
        "brief_title": "Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML", 
        "completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Myeloid Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must be between 18 and  60 years of age\n\n          -  Patients must have an ECOG Performance Status of  < 2\n\n          -  Patients must have a documented Unequivocal diagnosis of AML according to WHO 2008\n             classification (>20% blasts in the bone marrow), excluding M3 (acute promyelocytic\n             leukemia).\n\n          -  Patients must have a documented FLT3 ITD mutation, determined by local laboratory for\n             eligibility (historical tissue will be requested for central analysis confirmation)\n\n          -  Patients who have undergone allogeneic HSCT in CR1 from a matched related or matched\n             unrelated donor.   All of the following criteria must also be met:\n\n        HLA typing to include available 8/8 or 7/8 allele HLA matched donor (at A,B,C, DRB1)\n        Single allelic mismatch allowed \u2022 Patients who received a conditioning regimen which\n        included one of the following: Busulfan/Fludarabine (Bu/Flu) Busulfan (16 mg/kg PO or 12.8\n        mg/kg IV) Fludarabine (120-180 mg/m2) Fludarabine / Melphalan (Flu/Mel) Fludarabine\n        (120-180 mg/m2) Melphalan (\u2264 150 mg/m2) Busulfan/Cyclophosphamide (Bu/Cy) Busulfan (16\n        mg/kg PO or 12.8 mg/kg IV) Cyclophosphamide (120 mg/kg) Cyclophosphamide/Total Body\n        Irradiation (Cy/TBI) Cyclophosphamide (120 mg/kg) TBI (1200-1420 cGy)\n\n        \u2022 Recovery of counts by day 42 and able to start midostaurin by day 60 post-HSCT (first\n        dose of midostaurin to start no earlier than 28 days post-HSCT);  ANC >1000\u00b5L, platelets\n        \u226520,000 without platelet transfusion\n\n        Exclusion Criteria:\n\n          -  Patients whom have failed prior attempts at allogeneic HSCT\n\n          -  Patients who have received an autologous transplant\n\n          -  Patients with Acute GVHD Grade III-IV\n\n          -  Patients with a known confirmed diagnosis of HIV infection or active viral hepatitis.\n\n          -  Impaired cardiac function including any of the following:\n\n               -  Screening ECG with a QTc > 450 msec.  If QTc > 450 and electrolytes are not\n                  within normal ranges, electrolytes should be corrected and then the patient\n                  rescreened for QTc.\n\n               -  Patients with congenital long QT syndrome\n\n               -  History or presence of sustained ventricular tachycardia\n\n               -  Any history of ventricular fibrillation or torsades de pointes\n\n               -  Bradycardia defined as HR. < 50 bpm\n\n               -  Right bundle branch block + left anterior hemiblock (bifascicular block)\n\n               -  Patients with myocardial infarction or unstable angina < 6 months prior to\n                  starting study\n\n               -  Congestive Heart Failure  NY Heart Association class III or IV\n\n               -  Patients with an ejection fraction < 45% assessed by MUGA or ---ECHO within 28\n                  days prior to starting study cycle 1 (of midostaurin or control group)\n\n          -  Patients with any pulmonary infiltrate including those suspected to be of infectious\n             origin (unless resolves to \u2264 Grade 1 within screening timeframe)\n\n          -  Patient requires treatment with strong CYP3A4 inhibitors or moderate or strong CYP3A4\n             inducers other than those required for GVH or infection prophylaxis or treatment\n\n        Pregnant or nursing (lactating) women, or women of child-bearing potential, must use\n        highly effective methods of contraception during dosing and for 30 days after treatment\n        completion\n\n        Other protocol-defined inclusion/exclusion criteria may apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01883362", 
            "org_study_id": "CPKC412AUS23"
        }, 
        "intervention": [
            {
                "arm_group_label": "Standard of Care (SOC) with Midostaurin", 
                "description": "Midostaurin (PKC412) 50mg twice a day for 28 days of each cycle. Patients will be treated for 12 cycles.", 
                "intervention_name": "Midostaurin (PKC412)", 
                "intervention_type": "Drug", 
                "other_name": "PKC412, Midostaurin"
            }, 
            {
                "arm_group_label": "Standard of Care (SOC)", 
                "description": "Standard of Care is not defined per protocol. The investigator will prescribe based on the commonly used medications given in the post SCT setting.", 
                "intervention_name": "Standard of Care", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "4'-N-benzoylstaurosporine", 
                "Staurosporine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "acute myeloid leukemia", 
            "AML", 
            "FLT3-ITD", 
            "midostaurin", 
            "PKC412", 
            "allogeneic hematopoeitic stem cell tranplant", 
            "SCT", 
            "HSCT", 
            "CR1"
        ], 
        "lastchanged_date": "February 23, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Duarte", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91010"
                    }, 
                    "name": "City of Hope National Medical Center Oncology"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "contact": {
                    "phone": "310-825-5513"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90095"
                    }, 
                    "name": "University of California at Los Angeles Oncology"
                }, 
                "investigator": {
                    "last_name": "Gary Schiller", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "phone": "720-754-4800"
                }, 
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80218"
                    }, 
                    "name": "Sarah Cannon Research Institute"
                }, 
                "investigator": {
                    "last_name": "Patrick McSweeney", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "813-745-6012"
                }, 
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33612"
                    }, 
                    "name": "H. Lee Moffitt Cancer Center & Research Institute Oncology"
                }, 
                "investigator": {
                    "last_name": "Hugo Fernandez", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21231"
                    }, 
                    "name": "John Hopkins Kimmel Cancer Center Oncology"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "contact": {
                    "phone": "617-724-1124"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }, 
                    "name": "Massachusetts General Hospital Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Yi-Bin Chen", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "phone": "313-576-8760"
                }, 
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48201"
                    }, 
                    "name": "Wayne State University/Wertz Clinical Cancer Center Karmanos"
                }, 
                "investigator": {
                    "last_name": "Joseph P Uberti", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "phone": "507-284-2467"
                }, 
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55905"
                    }, 
                    "name": "Mayo Clinic - Rochester"
                }, 
                "investigator": {
                    "last_name": "Mark R. Litzow", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "phone": "314-454-8323"
                }, 
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }, 
                    "name": "Washington University School Of Medicine-Siteman Cancer Ctr Washington U School of Med"
                }, 
                "investigator": {
                    "last_name": "Camille N. Abboud", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "phone": "201-336-8297"
                }, 
                "facility": {
                    "address": {
                        "city": "Hackensack", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07601"
                    }, 
                    "name": "Hackensack University Medical Center Hackensack Univ Med Ctr (32)"
                }, 
                "investigator": {
                    "last_name": "Scott Rowley", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "phone": "212-639-3859"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10021"
                    }, 
                    "name": "Memorial Sloan Kettering Cancer Center Oncology"
                }, 
                "investigator": {
                    "last_name": "Sergio A Giralt", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "phone": "919-966-7746"
                }, 
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27599-9500"
                    }, 
                    "name": "University of North Carolina at Chapel Hill University of North Carolina 6"
                }, 
                "investigator": {
                    "last_name": "Thomas C. Shea", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }, 
                    "name": "Duke Clinical Research Institute Oncology"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "contact": {
                    "phone": "216-844-0130"
                }, 
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44106"
                    }, 
                    "name": "University Hospitals of Cleveland University Hosp Cleveland"
                }, 
                "investigator": {
                    "last_name": "Marcos de Lima", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43210"
                    }, 
                    "name": "Ohio State Comprehensive Cancer Center/James Cancer Hospital Ohio State University"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "contact": {
                    "phone": "503-494-8945"
                }, 
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97239"
                    }, 
                    "name": "Oregon Health Sciences University"
                }, 
                "investigator": {
                    "last_name": "Richard T. Maziarz", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "phone": "615-936-8422"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37232"
                    }, 
                    "name": "Vanderbilt Univeristy Oncology"
                }, 
                "investigator": {
                    "last_name": "Sanjay Mohan", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "phone": "615-329-7289"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Sarah Cannon Research Institute Sarah Cannon Research (SC)"
                }, 
                "investigator": {
                    "last_name": "Michael Savona", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "214-818-8471"
                }, 
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75246"
                    }, 
                    "name": "Baylor Health Care System/Sammons Cancer Center Oncology"
                }, 
                "investigator": {
                    "last_name": "Alan B. Miller", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "phone": "713-792-2921"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030-4009"
                    }, 
                    "name": "University of Texas/MD Anderson Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Richard Champlin", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "phone": "210-575-6904"
                }, 
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78229"
                    }, 
                    "name": "Texas Transplant Physicians Group Oncology 2"
                }, 
                "investigator": {
                    "last_name": "Carlos Bachier", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "phone": "206-667-1990"
                }, 
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98109"
                    }, 
                    "name": "Fred Hutchinson Cancer Research Center Oncology"
                }, 
                "investigator": {
                    "last_name": "Bart Scott", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madison", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53792"
                    }, 
                    "name": "University of Wisconsin Oncology"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5G 2M9"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase II, Randomized, Comparative Trial of Standard of Care, With or Without Midostaruin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With FLT3-ITD Mutated Acute Myeloid Leukemia", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone_ext": "+41613241111"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Jodi Virkus, Pharm D", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Relapse Free Survival (RFS)", 
            "safety_issue": "No", 
            "time_frame": "18 months from date of transplant"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01883362"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Disease Free Survival (DFS)", 
                "safety_issue": "No", 
                "time_frame": "for at least 24 months from date of transplant or study completion"
            }, 
            {
                "measure": "Non-Relapse Mortality (NRM)", 
                "safety_issue": "No", 
                "time_frame": "for at least 24 months from date of transplant or study completion"
            }, 
            {
                "measure": "Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "for at least 24 months from date of transplant or study completion"
            }, 
            {
                "measure": "FLT3-ITD mutation status centrally in archived material from diagnosis (if available) including mutant:wild type ratio", 
                "safety_issue": "No", 
                "time_frame": "upto 24 months from date of transplannt or at study completion"
            }, 
            {
                "description": "The assessment of safety will be based mainly on the frequency of Adverse Events (AEs), on the number of laboratory values summarized by CTCAE grades and non-relapse mortality(NRM). The assessment of tolerability will be based on whether midostaurin can be administered at a daily dose of 50mg twice daily at least 80% of the time to 50% or more of patients during the first 100 days after allogeneic HSCT", 
                "measure": "Number of Participants with Adverse Events as a Measure of Safety and Tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Pre-dose levels (Cmin) will be directly determined from raw plasma concentration-time data (units ng/ml)", 
                "measure": "Plasma Pharmacokinetics (PK) of midostaurin and the metabolites: CGP62221 and CGP52421: Pre-dose levels", 
                "safety_issue": "Yes", 
                "time_frame": "Pre-dose on days 1 and 15 of Cycle 1, on day 1 of Cycles 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12"
            }, 
            {
                "description": "Pre-dose levels (Cmin) will be directly determined from raw plasma concentration-time data (units ng/ml)", 
                "measure": "Plasma Pharmacokinetics (PK) of midostaurin and the metabolites: CGP62221 and CGP52421: Pre-dose levels", 
                "safety_issue": "Yes", 
                "time_frame": "Pre-dose collection two weeks following initiation of strong CYP3A4 inhibitors"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}